Paige Prostate

Paige Prostate is an AI-powered diagnostic tool that employs a convolutional neural network to analyze H&E stained whole-slide images from prostate biopsies, aiming to improve the accuracy and efficiency of prostate cancer detection by pathologists. The system was developed using extensive annotated slide data and demonstrates high sensitivity in identifying clinically significant cancers, serving as an adjunctive tool to support expert review and diagnosis.

Paige Prostate is an AI-driven digital pathology software designed to assist pathologists in the diagnosis of prostate cancer. It utilizes a convolutional neural network to analyze whole-slide hematoxylin and eosin (H&E) stained images obtained from prostate needle biopsies, meticulously scanning these images to identify and flag areas as either ‘suspicious’ or ‘not suspicious’ for cancer, and pinpointing the most probable location of a tumor for subsequent expert review. Developed and trained on an extensive dataset of thousands of annotated biopsy slides, Paige Prostate has demonstrated exceptional performance in validation studies. Notably, it achieved a sensitivity exceeding 98% for detecting clinically significant prostate cancers, specifically those with a Gleason score of ≥3+4, thereby minimizing the risk of missed diagnoses. Functioning as a computer-aided diagnosis (CADx) tool, Paige Prostate serves as a valuable adjunct, enhancing both the efficiency and accuracy of pathologists in the critical task of prostate cancer detection.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does Paige Prostate's performance (sensitivity and specificity) compare when applied to biopsy samples from diverse patient populations or those prepared with varying staining protocols?; What is the impact of Paige Prostate on pathologist workflow efficiency, specifically regarding turnaround time and inter-observer variability in Gleason grading?; Beyond flagging suspicious areas, can the system provide quantitative metrics or features that correlate with cancer aggressiveness or predict treatment response?; How does the system handle ambiguous cases or mimics of prostate cancer, and what is the false positive rate for lesions categorized as 'suspicious'?; What are the computational requirements for implementing Paige Prostate in a typical pathology lab, and how does it integrate with existing Laboratory Information Systems (LIS) and digital pathology viewers?